Highlights of This Issue 2919

SPECIAL FEATURES

New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Hans Prenen, Sabine Tejpar, and Eric Van Cutsem

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher and Simon P. Fricker

Control of Tumorigenesis and Chemoresistance by the DEK Oncogene
Erica Riveiro-Falkenbach and María S. Soengas

The Proapoptotic Molecule BLID Interacts with Bcl-Xl and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Sellier-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

Molecular Pathways

CXCL12 (SDF-1)/CXCR4 Pathway in Cancer
Beverly A. Teicher and Simon P. Fricker

Control of Tumorigenesis and Chemoresistance by the DEK Oncogene
Erica Riveiro-Falkenbach and María S. Soengas

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebrook, Todd M. Pits, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt

Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebrook, Todd M. Pits, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt

Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzetti, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzetti, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

CANCER THERAPY: PRECLINICAL

Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer

Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer
IMAGING, DIAGNOSIS, PROGNOSIS

3011 Fibroblast Growth Factor Receptor 3 Mutation Analysis on Voided Urine for Surveillance of Patients with Low-Grade Non-Muscle-Invasive Bladder Cancer
Tahlita C.M. Zuiverloon, Madelon N.M. van der Aa, Theo H. van der Kwast, Ewout W. Steyerberg, Hester F. Lingma, Chris H. Bangma, and Ellen C. Zwartboff

CANCER THERAPY: CLINICAL

3019 A Phase I Study of 5-Fluorouracil/Leucovorin and Arsenic Trioxide for Patients with Refractory/Relapsed Colorectal Carcinoma
Bach Ardalan, Pochi R. Subbarayan, Yipsel Ramos, Michael Gonzalez, Anthony Fernandez, Dmitry Mezentsev, Isildinha Reis, Robert Duncan, Lisa Podolsky, Kelvin Lee, Mayra Lima, and Parvin Ganji-Azar

3028 Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., and Maha H.A. Hussain

3035 Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi, Sari Pesonen, Sophie Escutenaire, Merja Särkioja, Mari Raki, Vincenzo Cerullo, Leena Laasonen, Ramon Alemany, Juan Rojas, Manel Cascallo, Kilian Guse, Maria Rajekci, Lotta Kangasniemi, Elna Haavisto, Aila Karioja-Kallio, Paivi Hannuksela, Minna Oksanen, Anna Kanerva, Timo Joensuu, Laura Abtaiainen, and Akseli Hemminki

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Creel, Kelly Mundy, S. Lindsay Davis, Ting Wang, Roula Albadine, Lucia Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Philipp G. Febo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, and Michael A. Carducci

Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers
Kevin J. Harrington, Eleni M. Karapanagiotou, Victoria Roulstone, Katie R. Twigger, Christine L. White, Laura Vidal, Debbie Beirne, Robin Prestwich, Kate Newbold, Merina Ahmed, Khin Thway, Christopher M. Nutting, Matt Coffey, Dean Harris, Richard G. Vile, Hardev S. Pandha, Johann S. DeBono, and Alan A. Melcher

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
ABOUT THE COVER

BLID expression was found to be lost or decreased in several invasive ductal breast carcinomas (IDC). The cover image shows an example of BLID-negative IDC as determined by immunohistochemistry using a breast tumor tissue microarray. Lack of BLID was associated with poor prognostic factors and survival. For details, see the article by Broustas and colleagues on page 2939 of this issue.